100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
WGU D027 Study Guide $9.99
Add to cart
Quickly navigate to
Preview
  2.  
  3. WGU D027
  4.  
  5. WGU D027

Exam (elaborations)

WGU D027 Study Guide
 0 purchase
  • Course
  • WGU D027
  • Institution
  • WGU D027

WGU D027 Study Guide 1. Autosomal Dominant 1 parent has, 50% change of child having 2. Autosomal Recessive Both parents are carriers, 25% change of child having, 50% chance child is a carrier. 3. Cystic Fibrosis affects pancreas causing secretions in lungs 4. 21st Trisomy Down Syndrome 5. Kl...

[Show more]

Preview 3 out of 16  pages

Document information

  • August 2, 2024
  • 16
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers

Subjects

Written for

  • WGU D027
  • WGU D027

Seller

avatar-seller
MERCYTRISHIA

Reviews received

Content preview

WGU D027 Study Guide

1. Autosomal Dominant 1 parent has, 50% change of child having
2. Autosomal Recessive Both parents are carriers, 25% change of
child having, 50% chance child is a carrier.
3. Cystic Fibrosis affects pancreas causing secretions in
lungs
4. 21st Trisomy Down Syndrome
5. Klinefelter Syndrome (XXY) male has extra X, female like qualities
6. Turner Syndrome Missing X in females
7. Alpha Thalassemia inherited blood disorder; mild to severe
anemia
8. Beta Thallasemia low hemoglobin; contraindicated medica-
tion ferrous sulfate
9. Prevalence Risk proportion of the population affected at a
certain time
10. Incidence rate number of new cases divided by popula-
tion
11. Innate immunity inflammation; increased vascular perme-
ability
12. B&T lymphocytes immune response
13. primary malignant tumor lack of organization of cells
14. glucocorticoids used in combination with other agent
to treat lymphoid tissue (leukemia). glu-
cocorticoids are directly toxic to lymphoid
tissues.
15. Selective estrogen receptor
modulators (SERM)




, WGU D027 Study Guide

for hormone receptor positive and ad-
vanced breast cancer. (Tamoxifin reduces
risk and recurrence risk)
16. Heart failure impairment of the ventricle to fill with or
eject blood; heart cannot meet metabolic
need of the body.
17. CHF heart cannot keep up with metabolic
needs; volume overload in pulmonary
area
18. Left Ventricular Dysfunction reduced ejection fraction; ventricle having
issue ejecting blood.
19. normal ejection fraction 55 - 60 % (blood pumped out with each
heartbeat)

20. Ejection fraction of 50% - re- preserved
duced or preserved?

21. Diastolic CHF preserved ejection fraction, problem is
with filling
22. Systolic CHF reduced ejection fraction, problem is with
ejecting
23. Left sided CHF pulmonary (JVD, fluid volume overload,
rails, S-3 murmurs) ** #1 cause of Right
sided CHF
24. BNP gold standard lab test to diagnose CHF
25. Echocardiogram Diagnostic tool, evaluates heart structure
and function
26. At Risk for HF - Stage A no structural heart disease or symptoms
of heart failure
27. Stage A HF co-morbidities




, WGU D027 Study Guide

htn, atherosclerotic disease, diabetes,
metabolic syndrome, patients using car-
diotoxins with family history
28. Therapy goals of stage A HF treat htn, encourage smoking cessation,
encourage regular exercise, treat lipid
disorders, discourage alcohol intake/drug
use, control metabolic syndrome
Meds: ACEI or Angiotensin II RB for vas-
cular disease or diabetes (avapro, losar-
tan, benicar, diovan, etc)
29. At Risk for HF - Stage B structural heart disease but no symptoms
of heart failure
30. Stage B HF co-morbidities previous MI, LV remodeling with LV hyper-
trophy and low EF, asymptomatic valvular
disease
31. Therapy goals of Stage B HF Meds: ACEI or ARB, Beta-blockers, in-
plantable defibrillators
32. Stage C heart failure structural heart disease with prior or cur-
rent symptoms of HF
33. Presentation of Stage C HF known structural heart disease and short-
ness of breath and fatigue, reduced exer-
cise tolerance
34. Therapy for Stage C HF dietary salt restriction, MEDS: diuretic,
ACEI, beta blockers. Some patients: al-
dosterone antagonist, ARBs, digitalis, hy-
dralazine/nitrates, biventricular pacing, in-
plantable defibrillators
35. Stage D heart failure refractory HF requiring specialized inter-
ventions
36. Presentation of Stage D HF marked symptoms at rest despite maxi-
mal medical therapy (recurrently hospital-

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller MERCYTRISHIA. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $9.99. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

69052 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling
$9.99
  • (0)
Add to cart
Added